WELL Health Technologies (WELL.TO) Buy, Sell…

Home

Daily Stock Opinions and Ratings

WELL Health Technologies (WELL.TO)

4.34

+0.03 (0.70%)

as of Aug 25, 2026, 7:59:59 pm Market Open.

296 watching

Investor Insights

Aug 26, 2026, 12:00 am

This summary was created by AI, based on 14 opinions in the last 12 months.

WELL Health Technologies is experiencing a complex phase marked by significant strategic changes, including the divestiture of non-core US operations and the planned IPO of its technology subsidiary, Wellstar. Despite a strong revenue growth of 56% year-over-year and positive organic growth of 19%, the stock struggles with perception issues and volatile market sentiment. Many experts note that the market is in a wait-and-see mode, and the company needs to demonstrate clearer growth synergies and execution on its strategies. Although analysts have recognized its cheap valuation relative to earnings, underlying uncertainties regarding acquisitions and market dynamics pose risks. Overall, while the fundamentals may appear solid on paper, investor confidence seems fragile, necessitating patience and a clearer path to growth.

Consensus

Mixed

Valuation

Undervalued

Similar

Knight, KNT

WAIT

Shares recently dropped over disappointing margins and profits, but they are the best in telehealth. Also, they made puzzling acquisitions. But the CEO has a great track record and blue-chop investors are involved. The stock isn't going anywhere, but the market wants to see better profits.

Wealthica Track your Stocks in your Watch List

BUY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

WELL is up 84% YTD and not that far from its 52-week high. It ran up hard this year and the drop does look like profit-taking to us since there really was no negative news. We would consider it buyable today. For the Canadian sector we see it as quite attractive.
Unlock Premium - Try 5i Free

BUY

It has had a very strong start to 2023 and has had minimal impacts from inflation and supply chain issues. It has 95% recurring revenue and organic growth of 21% year over year. Trades at 13.3 X EBITDA.

BUY

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

2024 Expectations :

Q4 EPS 3.7c; revenue $146.1M.

2022 EPS 12c; revenue $538.5M

2023 EPS 21c; revenue $621M

We would consider it a buy today.
Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Fantastic CEO that has history of success
Aggregator of healthcare companies.
Valuation and profitability not in a great space.
Wants to see consistent profitability.

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Strategy of acquiring clinics and digital assets. Strong player in digital health space in Canada. Entry into lucrative US market. Expensive valuation; high share price risk.

BUY

WATCH

Doesn't see them going into medical marijuana. They're looking for businesses they can easily absorb and expand their distribution. They're doing very well now. Has owned this in the past and is watching it. Is waiting for the market to stabilize.

HOLD

Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Valuation has come to down significantly. Greater focus on organic growth. Potential to be a long-term dominant player. Taken on more debt.

DON'T BUY

Covered his short in June, as it had fallen too far, too fast. If it stays expensive, it may end up a hedge for him again. If it starts growing into its valuation, it could be a long. It's down to the metrics. Right now, he'd avoid.

BUY

It should continue to integrate the telehealth side with traditional medicine. Got extended during the pandemic and has come back down to earth. Once the rotation from shareholders is over, the stock will continue to build a base on earnings and then move up. Recent numbers were decent and he has re-added.

DON'T BUY

Not a profitable company that will struggle with rising interest rates. Better places for capital. Wait until later date to invest. Business model in the long term will survive (healthcare will always be required).

WATCH

It continues to grow and execute and management has delivered, but the market isn't interested in this type of stock. It did a recent acquisition and financial raise. It is building a digital platform for doctors - patient records etc.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. EPS of $0.03 beat estimates and revenues were also ahead of expectations at $115.68M. Revenues increased 573% yoy for the quarter. Management expects 2022 revenues to top $500M and the company should be profitable. Very good results. Unlock Premium - Try 5i Free

DON'T BUY

The founding CEO has an excellent track record. He owned his previous company which did well. The valuation ripped higher and got ahead of itself--not their fault. However, in healthcare tech, there are names with better PEs.

Showing 46 to 60 of 80 entries

Most Recent Experts

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

WELL Health Technologies (WELL.TO)